Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5731)
All Articles published online
|
Dec 28, 2007 (publication date) through Jun 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Smirnova OV, Ostroukhova TY, Bogorad RL. JAK-STAT pathway in carcinogenesis: Is it relevant to cholangiocarcinoma progression. World J Gastroenterol 2007; 13(48): 6478-6491 [PMID: 18161917 DOI: 10.3748/wjg.v13.i48.6478] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i48/6478.htm |
| Number | Citing Articles |
| 1 |
C H Lee, C J Chang, Y J Lin, C N Yeh, M F Chen, S Y Hsieh. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. British Journal of Cancer 2009; 100(11): 1765 doi: 10.1038/sj.bjc.6605063
|
| 2 |
Baohong Liu, Xingxing Xiao, Ziqin Lin, Yongliang Lou, Lingling Zhao. PDGFRB is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer. Cancer Biomarkers 2022; 34(2): 251 doi: 10.3233/CBM-210335
|
| 3 |
Po-Lin Kuo, Wen-Chiu Ni, Eing-Mei Tsai, Ya-Ling Hsu. Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells. Molecular Cancer Therapeutics 2009; 8(5): 1328 doi: 10.1158/1535-7163.MCT-08-0914
|
| 4 |
Celina Ang, Sonia Reichert, Randall F. Holcombe. The American Cancer Society's Oncology in Practice. 2018; : 117 doi: 10.1002/9781118592168.ch8
|
| 5 |
Ru-Nan Yu, Cheng-Juan Chen, Lei Shu, Yuan Yin, Zhi-Jian Wang, Tian-Tai Zhang, Da-Yong Zhang. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors. Bioorganic & Medicinal Chemistry 2019; 27(8): 1646 doi: 10.1016/j.bmc.2019.03.009
|
| 6 |
Teklie Mengie Ayele, Zelalem Tilahun Muche, Awgichew Behaile Teklemariam, Achenef Bogale, Endeshaw Chekol Abebe. Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review. Journal of Inflammation Research 2022; : 1349 doi: 10.2147/JIR.S353489
|
| 7 |
Guan Lin, Zhang Xinhe, Tian Haoyu, Li Yiling. Aberrantly methylated-differentially expressed genes and related pathways in cholangiocarcinoma. Medicine 2022; 101(25): e29379 doi: 10.1097/MD.0000000000029379
|
| 8 |
Bo Zhai, Xue-Ying Sun. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World Journal of Hepatology 2013; 5(7): 345-352 doi: 10.4254/wjh.v5.i7.345
|
| 9 |
Mark Carfagna, Ellen Cannady, Thomas Ryan, Jay Herman, Lew Truex, Kanchan Narwani, John Sullivan. Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats. Regulatory Toxicology and Pharmacology 2018; 92: 458 doi: 10.1016/j.yrtph.2017.11.020
|
| 10 |
Wenjun Du, Fuli Zhang, Pei Yan, Qingfu Lai, Junjian Li, Daqian Zhu, Lianbao Ye. Design, Synthesis, Activity Evaluation and Molecular Docking Study of Novel Janus kinase Inhibitors. ChemistrySelect 2021; 6(17): 4212 doi: 10.1002/slct.202100707
|
| 11 |
HASAYA DOKDUANG, PUANGRAT YONGVANIT, NISANA NAMWAT, CHAWALIT PAIROJKUL, SAKKARN SANGKHAMANON, MIKA SAKURAI YAGETA, YOSHINORI MURAKAMI, WATCHARIN LOILOME. Xanthohumol inhibits STAT3 activation pathway leading to growth suppression and apoptosis induction in human cholangiocarcinoma cells. Oncology Reports 2016; 35(4): 2065 doi: 10.3892/or.2016.4584
|